Telos forecasts $198.2M-$200.7M 2026 revenue while phasing out $32M low-margin resale in 2027
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Finance & Markets
Botswana De Beers Major Shareholder In Global Diamond Consortium Deal
Botswana’s stake to increase from 15% to 30% in an expected deal with the Global Diamond Consortium of jewelry industry players.
New Oriental Education: 3 Key Takeaways for Long-Term Investors
Key PointsNet revenue grew 23.1% year over year to $1.87 billion.
PPG: 3 Key Takeaways for Long-Term Investors
Key PointsCommercial pricing actions fully offset cost inflation within six months.
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.